U. Müller-Richter

Statistics

Publications

Citations

H-Index

Active since

2022

Affiliations

National Institute of Oncology(Current)

Charité - Universitätsmedizin Berlin

Norton Healthcare

BioNTech (Germany)

Montefiore Medical Center

U. Müller-Richter is an author at National Institute of Oncology specializing in vaccine-based immunotherapy, cancer vaccine development, and rna vaccine immunotherapy.

Publications per year

2022–2024

Publications

155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT

K. Klinghammer, N.F. Saba, E. Castelluci et al. · Immuno-Oncology Technology · 2022 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17

877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC

Nabil F. Saba, K. Klinghammer, E. Castelluci et al. · Annals of Oncology · 2024 · 12 citations · Full text

Medicine, Immunology, Oncology +17

1–2 of 2